T0	Outcomes 977 1009	from baseline to week 18 in 6MWD
T1	Outcomes 1096 1125	week 18, WHO functional class
T2	Outcomes 1265 1277	respectively
T3	Outcomes 1361 1373	(P = 0.090).
T4	Outcomes 1374 1388	Adverse events
T5	Outcomes 1445 1528	100 mg) included headache, peripheral edema, dizziness, nausea, extremity pain, and
T6	Outcomes 1605 1641	100 mg improved functional class but